Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11985509 | 1.00 | LMNA (0.48) | LMNAADRA2AADRA2CHIF1AKDM4E | |
| SCHEMBL8279099 | 1.00 | LMNA (0.48) | LMNAADRA2AADRA2CHIF1AKDM4E | |
| Hydrochloric Acid SCHEMBL3954994 | 0.98 | ALDH1A1 (0.50) | LMNAADRA2AADRA2CHIF1AKDM4E | |
| Phenylglycine SCHEMBL28116072 | 0.86 | CYP2D6 (0.50) | LMNAADRA2AADRA2CHIF1AKDM4E | |
| Acetic Acid SCHEMBL27430362 | 0.84 | ALOX5 (0.46) | LMNAADRA2AADRA2CHIF1AKDM4E | |
| Phenylglycine SCHEMBL159420 | 0.82 | CYP2D6 (0.56) | LMNAKDM4ECYP2D6SRCDPP4 | |
| SCHEMBL946139 | 0.82 | DPP4 (0.50) | LMNAADRA2AADRA2CHIF1AKDM4E | |
| SCHEMBL28363604 | 0.82 | DPP4 (0.50) | LMNAADRA2AADRA2CHIF1ACYP2D6 | |
| Phenylglycine SCHEMBL157180 | 0.82 | CYP2D6 (0.56) | LMNAKDM4ECYP2D6SRCDPP4 | |
| Phenylglycine SCHEMBL30559595 | 0.82 | CYP2D6 (0.56) | LMNAKDM4ECYP2D6SRCDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | claimed |
| US-6743791-B2 | ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-01 | — | — | US | claimed |
| EP-1363906-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-11-26 | — | — | EP | claimed |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | claimed |
| WO-2002064586-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-22 | — | — | WO | claimed |
| US-20230227420-A1 | PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | EMPATHBIO, INC. | 2023-07-20 | — | — | US | disclosed |
| CN-111187176-B | Method for preparing N-vinyl amide compound under catalysis of copper salt | 浙江工业大学 | 2022-11-25 | — | — | CN | disclosed |
| WO-2021158869-A1 | COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES AND NERVE DAMAGE, AND METHODS FOR PREPARING COMPOUNDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-3851447-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BHI Limited Partnership (CA) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020110056-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-06-04 | — | — | WO | disclosed |
| CN-111187176-A | Method for preparing N-vinyl amide compound under catalysis of copper salt | 浙江工业大学 | 2020-05-22 | — | — | CN | disclosed |
| CN-110627704-A | Preparation method of bazedoxifene | 艾瑞吉瑞股份公司 | 2019-12-31 | — | — | CN | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-18 | — | — | US | disclosed |
| CN-1298867-A | Process for preparing alpha-amidophenylketone with optical activity | AIKE PHARMACEUTICAL SCIENCE AN (CN) | 2001-06-13 | — | — | CN | disclosed |
| US-6160128-A | Tritioacetylating reagents and processes for preparation thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-12-12 | — | — | US | disclosed |
| EP-1054865-A1 | FARNESYL TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999041235-A1 | FARNESYL TRANSFERASE INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-08-19 | — | — | WO | disclosed |
| EP-0092239-A2 | Oxazole derivatives, production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1983-10-26 | — | — | EP | disclosed |
| US-4069385-A | FROM AN OLEFIN AND AN ORGANIC PEROXIDE WITH COPPER-SCHIFF BASE COMPEX AS CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227420-A1 | PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | COMT, PNMT, ABCB1 | LMNA 2528/4885ADRA2A 394/4885ADRA2C 391/4885 |
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | LMNA 3326/4885ADRA2A 1155/4885ADRA2C 1174/4885 |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | LMNA 3326/4885ADRA2A 1155/4885ADRA2C 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.